Traditional and novel diagnostic biomarkers for acute myocardial infarction

Abstract Background Acute myocardial infarction (AMI) is a leading cause of death worldwide. The first hours acute are correlated with the highest risk death. Therefore, early diagnosis seriously affects efficacy treatment administered to patient. Misdiagnosing patients chest pain often leads inappropriate admission them as patients. physical examination patient, electrocardiogram, and assessment cardiac biomarkers all play an important role in ischemia, along patient's medical history. Main body present review highlights number different that released elevated blood during infarction. Conclusions Analysis has become first-line diagnostic tool used Novel markers infarction, when added routinely markers, can provide value not only earlier detection but also monitoring clinical progress disease, predicting its consequences, evaluating prognosis, detecting recurrence, managing treatment. This lower mortality rate associated cMyC, IMA, S100, MicroRNAs serve whereas myeloperoxidase, sCD40L, PAPPA, TNF-α be monitor disease. In addition, H-FABP, GDF-15, F2 isoprostanes, ST2 predictors AMI complications mortality. Copeptin, ST2, SIRT useful prognostic